Pluripotent Stem Cell Evaluation Agreement Between Roslin Cells and Pfizer for Regenerative Medicine Development
Roslin Cells and Pfizer Limited have signed an agreement for Pfizer to evaluate Roslin’s GMP quality pluripotent stem cells (PSC).
The evaluation will allow Pfizer access to Roslin’s Cell lines with a view to assessing the potential for specific clinical therapies. The agreement is the first time Roslin’s GMP cell lines have been evaluated by one of the major pharmaceutical companies.
Aidan Courtney, Roslin Cells CEO commented ‘We have made a substantial investment in establishing the capability to derive new stem cell lines to the standards required for their use as the starting material for a clinical therapy. They are already being used in our own collaborative research programmes and I am delighted that they will now be evaluated for potential use by Pfizer.’
Commercial terms are confidential and not disclosed.
Other news from the department business & finance
